3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Magnetic Resonance Spectroscopy
6
Biopsy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
4
Cisplatin
3
Carboplatin
3
tazemetostat
2
selpercatinib
2
larotrectinib
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Topotecan
2
Temozolomide
2
Surveys and Questionnaires
2
Radiation
2
LY3023414
2
Gemcitabine
2
Etoposide
2
Cyclophosphamide
2
ulixertinib
1
tipifarnib
1
pegfilgrastim
1
palbociclib
1
olaparib
1
niraparib
1
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
RAD1901
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled